Search

Displaying results 2711 - 2720 of 4207 in total
  1. Drug

    RLYB212

    go.drugbank.com/drugs/DB17727
    Investigational

    It is currently being developed by Rallybio for the prevention of fetal and neonatal alloimmune thrombocytopenia.

  2. Drug

    SAR-439459

    go.drugbank.com/drugs/DB17864
    Investigational

    [A259862] Developed by Sanofi, it is being investigated for the treatment of cancers and Osteogenesis Imperfecta.

  3. Drug

    Beractant

    go.drugbank.com/drugs/DB06761
    Approved

    Beractant is a pulmonary surfactant used for the treatment of Respiratory Distress Syndrome (RDS) in premature infants. Considered a natural source of surfactant as it is made from bovine lung extract, beractant contains a mixture of pho...

  4. Drug

    Sinecatechins

    go.drugbank.com/drugs/DB01266
    ApprovedInvestigationalNutraceutical

    Catechins constitute 85 to 95% (by weight) of the total drug substance which includes more than 55% of Epigallocatechin gallate (EGCg), other catechin derivatives such as Epicatechin (EC), Epigallocatechin

  5. Drug

    Manganese cation

    go.drugbank.com/drugs/DB06757
    ApprovedInvestigationalNutraceutical

    [A263687, A263662] In humans, manganese regulates several physiological processes by acting as a cofactor for proteins [A263657, A263662, A263667] making it an essential metal for normal development and

  6. Drug

    Flavin mononucleotide

    go.drugbank.com/drugs/DB03247
    ApprovedInvestigational

    [L54226] In addition to its systemic use as a means of riboflavin supplementation, a topical ophthalmic preparation of FMN was approved by the FDA in October 2025 for use as a photoenhancer in epithelium-on

  7. Drug

    Inositol nicotinate

    go.drugbank.com/drugs/DB08949
    ApprovedWithdrawn

    It is associated with reduced flushing compared to other vasodilators by being broken down into the metabolites and inositol at a slower rate.

  8. Drug

    Mirikizumab

    go.drugbank.com/drugs/DB14910
    ApprovedInvestigational

    Mirikizumab is a monoclonal antibody developed by Eli Lilly intended to treat ulcerative colitis.

  9. Drug

    Toripalimab

    go.drugbank.com/drugs/DB15043
    ApprovedInvestigational

    One mechanism by which this occurs is through the overexpression of programmed cell death ligand (PD-L1)[A261506] - the binding of PD-L1 (and PD-L2) to its target receptor (PD-1) results in the inhibition

  10. Drug

    Ioxaglic acid

    go.drugbank.com/drugs/DB09313
    ApprovedWithdrawn

    Ioxaglic acid is marketed as Hexabrix. This drug is an ionic tri-iodinated benzoate used as a low-osmolality contrast agent during diagnostic imaging procedures. Like other organic iodine compounds, ioxaglic acid blocks x-rays and is opa...